Medicine's pattern recognition is splitting into two jobs. For a century, the pathologist's eye read tissue slides and assigned a score. The new work, the work that AI on these studies actually does, is to read a different layer entirely: where immune cells cluster inside a tumor, not just how many there are. The pathologist still scores the count. The machine quantifies the geography. These are no longer competing answers to the same question; they are different questions, asked of the same slide.
Prof Sherene Loi's two Lancet Oncology studies, covering more than 5,600 breast cancer patients, frame this directly. Her Peter MacCallum Cancer Center team's finding is not that AI and pathologists agree. The studies say the two scores were not identical. They say the AI scored a spatial layer, the "hotspots" of tumor-infiltrating lymphocytes, that the pathologist's eye does not readily quantify, and that layer added its own prognostic information on top of the count.
That is a reusable mechanism, not a one-off. Whenever a clinical score rests on a human reading of structure, machine vision will first match the human reading and then quietly pull out a layer the reading never measured. The replacement narrative ages badly. The layer-extraction narrative ages into a long, durable shift in what a diagnosis can see.
Reported by Sky for Type0, from AI as good as humans at predicting breast cancer outcomes: studies. Read the original: australianherald.com